Welcome to the first-ever Big4Bio Year-in-Review for the Philadelphia area!
We hope you enjoy looking back on 2019’s top stories, deals, and M&A that went down in Philadelphia’s research, pharma, and biotech sectors as you look to a productive 2020.
The Greater Philadelphia region has finally come into its own in the life science world! While life sciences venture investment fell across the nation, the area’s life sciences companies bore witness to a near tripling of venture capital investment. And early stage investments doubled! Philadelphia was also the city where the largest M&A deal of the year took place—Bristol-Myers Squibb’s $74 billion buyout of Celgene.
- Facts about Greater Philadelphia’s life sciences industry
- The most-clicked stories of the Big4Bio:Philadelphia newsletter
- Venture investment figures, top deals, and major M&A
- Our outlook for 2020
The year 2019 has been a spectacular one for the Greater Philadelphia life sciences community.
Despite the issues that the presidential election year might bring, Philadelphia is likely to continue to do well in the cell and gene therapy markets—with the backing of NIH funding and a supply of life sciences graduates.
From now on, you can look out for a Year-in-Review report from Big4Bio for each region, every year! In the future, Big4Bio intends to include more parameters and deeper analyses in these yearly reports. We’d like to thank our partners and sponsors for making this venture a possibility.